2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapy
2013
Efficacy and safety of long‐acting intramuscular testosterone undecanoate in aging men: a randomised controlled study
Tan W, Low W, Ng C, Tan W, Tong S, Ho C, Khoo E, Lee G, Lee B, Lee V, Tan H. Efficacy and safety of long‐acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International 2013, 111: 1130-1140. PMID: 23651425, DOI: 10.1111/bju.12037.Peer-Reviewed Original ResearchConceptsProstate-specific antigenTestosterone undecanoateTestosterone deficiencyTreatment armsAdverse eventsSex hormone-binding globulinIntramuscular testosterone undecanoateCommon adverse eventsIncreased serum testosteroneHormone-binding globulinLiver function testsCessation of treatmentFasting blood glucosePhysical examination resultsRandomised controlled studySite of injectionTU injectionsPlacebo armSerum TTSerum testosteroneSpecific antigenAdverse reactionsLipid profileFunction testsControlled studies